Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

Ryota Tamura; Masato Fujioka; Yukina Morimoto; Kentaro Ohara; Kenzo Kosugi; Yumiko Oishi; Mizuto Sato; Ryo Ueda; Hirokazu Fujiwara; Tetsuro Hikichi; Shinobu Noji; Naoki Oishi; Kaoru Ogawa; Yutaka Kawakami; Takayuki Ohira; Kazunari Yoshida; Masahiro Toda

doi:10.1038/s41467-020-16007-z

Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

Ryota Tamura, Masato Fujioka, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda

研究成果: Comment/debate › 査読

3 被引用数 (Scopus)

抄録

The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

本文言語	English
論文番号	2028
ジャーナル	Nature communications
巻	11
号	1
DOI	https://doi.org/10.1038/s41467-020-16007-z
出版ステータス	Published - 2020 12月 1

ASJC Scopus subject areas

化学 (全般)
生化学、遺伝学、分子生物学（全般）
一般
物理学および天文学（全般）

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1038/s41467-020-16007-z

他のファイルとリンク

フィンガープリント

「Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Tamura, R., Fujioka, M., Morimoto, Y., Ohara, K., Kosugi, K., Oishi, Y., Sato, M., Ueda, R., Fujiwara, H., Hikichi, T., Noji, S., Oishi, N., Ogawa, K., Kawakami, Y., Ohira, T., Yoshida, K., & Toda, M. (2020). Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1). Nature communications, 11(1), [2028]. https://doi.org/10.1038/s41467-020-16007-z

Tamura, R, Fujioka, M, Morimoto, Y, Ohara, K, Kosugi, K, Oishi, Y, Sato, M, Ueda, R , Fujiwara, H, Hikichi, T, Noji, S, Oishi, N, Ogawa, K, Kawakami, Y, Ohira, T, Yoshida, K & Toda, M 2020, 'Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)', Nature communications, vol. 11, no. 1, 2028. https://doi.org/10.1038/s41467-020-16007-z

@article{3d6383a3f6854124bb46faa8c14df50a,

title = "Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)",

abstract = "The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.",

author = "Ryota Tamura and Masato Fujioka and Yukina Morimoto and Kentaro Ohara and Kenzo Kosugi and Yumiko Oishi and Mizuto Sato and Ryo Ueda and Hirokazu Fujiwara and Tetsuro Hikichi and Shinobu Noji and Naoki Oishi and Kaoru Ogawa and Yutaka Kawakami and Takayuki Ohira and Kazunari Yoshida and Masahiro Toda",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-16007-z",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Author Correction

T2 - A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

AU - Tamura, Ryota

AU - Fujioka, Masato

AU - Morimoto, Yukina

AU - Ohara, Kentaro

AU - Kosugi, Kenzo

AU - Oishi, Yumiko

AU - Sato, Mizuto

AU - Ueda, Ryo

AU - Fujiwara, Hirokazu

AU - Hikichi, Tetsuro

AU - Noji, Shinobu

AU - Oishi, Naoki

AU - Ogawa, Kaoru

AU - Kawakami, Yutaka

AU - Ohira, Takayuki

AU - Yoshida, Kazunari

AU - Toda, Masahiro

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

AB - The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

UR - http://www.scopus.com/inward/record.url?scp=85083758821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083758821&partnerID=8YFLogxK

U2 - 10.1038/s41467-020-16007-z

DO - 10.1038/s41467-020-16007-z

M3 - Comment/debate

C2 - 32317644

AN - SCOPUS:85083758821

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2028

ER -